Table 1.
Ongoing clinical trials related to epigenetic targets and regulation of aging
| Interventions | Conditions/diseases | Trial nO. | Phase |
|---|---|---|---|
| Diet intervention | Epigenetic aging | NCT04962464 | 2 |
| Epigenetic aging | NCT05297097 | 2 | |
| Epigenetic aging | NCT05234203 | NA | |
| Aging | NCT05424042 | NA | |
| Exercise | Aging | NCT05232968 | NA |
| Aging; Alzheimer disease | NCT04299308 | NA | |
| Biological aging | NCT03440099 | NA | |
| Aging; Inflammatory response | NCT05042167 | NA | |
| NMN | Glucose metabolism disorders | NCT04571008 | NA |
| Hypertension | NCT04903210 | 4 | |
| Physical activity; Muscle recovery | NCT04664361 | NA | |
| NR | Aging | NCT03818802 | NA |
| Parkinson disease | NCT03568968 | NA | |
| Overweight and obesity; Aging; Type 2 diabetes | NCT04907110 | NA | |
| Sarcopenia; Nicotinamide adenine dinucleotide concentration; Muscle quality and NAD+ content | NCT04691986 | NA | |
| STACs | Vascular resistance; Hypertension | NCT01842399 | 1/2 |
| Healthy | NCT00996229 | 3 | |
| Metformin | Epigenetic aging; Immunosenescence | NCT04375657 | 2 |
| Aging; Insulin sensitivity; Chronic disease; Mitochondria; Insulin resistance | NCT04264897 | 3 | |
| Frailty; Sarcopenic obesity; Aging | NCT04221750 | 3 | |
| Frailty | NCT02570672 | 2 | |
| Mild cognitive impairment | NCT04098666 | 2/3 | |
| Insulin resistance; Obesity | NCT03733132 | 2 | |
| Rapamycin | Epigenetic clock of skin | NCT04608448 | 1 |
| Aging | NCT04488601 | 2 | |
| Aging | NCT04742777 | 2 | |
| Mild cognitive impairment; Alzheimer disease | NCT04629495 | 2 | |
| Mild cognitive impairment; Alzheimer disease | NCT04200911 | 1 | |
| D + Q | Epigenetic aging | NCT04946383 | 2 |
| Diabetic kidney disease | NCT02848131 | 1 | |
| Alzheimer disease | NCT04063124 | 1/2 | |
| Mild cognitive impairment; Alzheimer disease | NCT04785300 | 1/2 | |
| Alzheimer disease; Mild cognitive impairment | NCT04685590 | 2 | |
| Aging-related osteoporosis | NCT04313634 | 2 |